anti cancer agents articles & resources on Made-in-China.com

The Patent Application Covers Synta's Proprietary HDC Technology

Nov 4, 2013

Synta Pharmaceuticals has announced the publication of the company's first patent application covering its proprietary Hsp90-inhibitor drug conjugate (HDC) platform, which leverages the company's expertise in chaperone biology and medicinal ...

Tags: Health, Medicine

Rexahn Has Entered Into an Exclusive Licensing Agreement with The University of Maryland

Jul 18, 2013

Clinical stage biopharma company Rexahn Pharmaceuticals has entered into an exclusive licensing agreement with the University of Maryland, Baltimore (UMB), for a novel drug delivery platform, which targets the delivery of chemotherapeutic ...

Tags: Rexahn Pharma, Oncology Drug

OncoSec Medical Has Obtained CE Certification to Treat Solid Tumor Cancers

Dec 18, 2012

OncoSec Medical has obtained CE certification for its proprietary gene and drug delivery technology, designed to treat solid tumor cancers. The assessment and certification process was supervised by SGS Group, a provider of inspection, ...

Tags: OncoSec, CE certification, proprietary gene, drug delivery technology

Critical Outcome Has Received a Patent for Its Advanced Oncology Drug Candidate

Dec 5, 2012

Critical Outcome Technologies has received a patent for its advanced oncology drug candidate, from the US Patent and Trademark Office. The patent covers the synergistic effects of combination therapies containing COTI-2 and members of ...

Tags: oncology drug, COTI-2, anti cancer agents

anti cancer agents

The Patent Application Covers Synta's Proprietary HDC Technology

Rexahn Has Entered Into an Exclusive Licensing Agreement with The University of Maryland

OncoSec Medical Has Obtained CE Certification to Treat Solid Tumor Cancers

Critical Outcome Has Received a Patent for Its Advanced Oncology Drug Candidate

Related Products